Boston, MA – According to filings with the U.S. Securities and Exchange Commission, TScan Therapeutics is raising $23,300,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Southwell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TScan Therapeutics

T-cell therapy unlocks the power of the immune system by reprogramming T cells to detect and eliminate cancer cells. The potential of this approach remains largely untapped, however, due to the lack of identified targets. We are addressing this challenge using our proprietary genome-wide, high-throughput platform to identify the natural targets of anti-tumor T cells residing in the tumors of cancer patients. When we identify a novel target, we simultaneously identify a T cell receptor (TCR) that recognizes that target and can potentially be used in safe and effective TCR T-cell therapy.

To learn more about TScan Therapeutics, visit http://www.tscan.com/

Contact:
David Southwell, Chief Executive Officer
857-399-9500
southwell@tscan.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved